The Seattle Seahawks were Super Bowl 60 champions, but now that we’ve passed free agency, the 2026 NFL Draft and the schedule has been released, it’s a good time to take stock of the Super Bowl odds ...

Early indications suggest Disney’s lofty Super Bowl advertising expectations might have hit a speed bump. Disney was seeking advertisers willing to commit a $10 million “match” to go along with any ...

On the heels of the 2026 NFL Draft kicking off in Pittsburgh on April 23, rumors have swirled online that Nashville will host an upcoming Super Bowl. The speculation stemmed from sportscaster Dan ...

Disney is aiming high with its asking price for 30-second ad spots in the 2027 telecast of Super Bowl LXI, which marks the company’s first time televising the Super Bowl in 20 years. Perhaps too high, ...

Disney‘s run to its first Super Bowl touchdown in 20 years is in danger of being stymied by some serious defense. The company has told advertisers it believes they should pay $10 million for a ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives to roughly triple its footprint by 2030. The three initiatives include the new ...

Inclusive Health Accelerators (IHAs): a new community-based initiative launching across five U.S. cities this week, which aims to close gaps in access to breast and prostate cancer care communities ...

The Super Bowl is heading back to the Sin City. The NFL announced on Monday during the NFL Annual Meeting that the Super Bowl will return to Las Vegas' Allegiant Stadium in 2029, five years after the ...

The National Football League announced that Las Vegas will host Super Bowl LXIII in 2029 at Allegiant Stadium. The announcement was made today at the NFL Annual Meeting in Phoenix, following a review ...

Novartis is facing a class-action lawsuit alleging it shared, without patients’ consent, sensitive health information it collected from visitors to its consumer-facing branded drug websites. The ...

Breast cancers driven by a particular genetic signature can already be treated by a particular class of targeted therapies, but the race is on to develop next-generation medicines that improve the ...

Novartis plans to spend up to $3 billion to buy an experimental breast cancer drug from Delaware-based startup Synnovation Therapeutics. As part of the deal to boost its oncology portfolio, the Swiss ...